Effects of oral contraceptives on breast epithelial proliferation

被引:76
作者
Isaksson, E [1 ]
von Schoultz, E
Odlind, V
Söderqvist, G
Csemiczky, G
Carlström, K
Skoog, L
von Schoultz, B
机构
[1] Karolinska Hosp, Dept Oncol, Radiumhemmet, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Dept Obstet & Gynecol, S-17176 Stockholm, Sweden
[3] Karolinska Hosp, Dept Pathol & Cytol, S-17176 Stockholm, Sweden
[4] Huddinge Univ Hosp, Karolinska Inst, Dept Obstet & Gynecol, S-14186 Huddinge, Sweden
关键词
breast epithelial proliferation; progestogen; oral contraceptives; levonorgestrel;
D O I
10.1023/A:1006482418082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The association between oral contraceptive (OC) use and breast cancer is not fully understood. Estrogen is a known mitogen to breast epithelial cells, but there is still a controversy about the effect of added progestogens. Fine needle aspiration (FNA) biopsies were used to assess epithelial proliferation in normal breast tissue from 106 healthy premenopausal women with and without oral contraceptives. In 26 women biopsies were performed before and after 2 months of OC use. Proliferation, expressed as percentage of Ki-67/MIB-1 positive cells, was correlated to endogenous progesterone, androgenic/anabolic compounds and exogenous progestogen. We found a higher proliferation (p = 0.03) in OC users compared to non users, with mean values of 4.8% and 2.2%, respectively. There was a positive correlation between proliferation and progesterone levels in non-users and with serum levonorgestrel concentrations in women using OCs containing this progestogen (rs = 0.43, p = 0.02). Women using OCs had significantly lower serum androgen levels compared to naturally cycling women and free testosterone levels displayed an inverse relation to breast epithelial proliferation. There was a marked variation in the response to exogenous sex steroids. In certain women after 2 months of OC use, the percentage of MIB-1 positive cells was as high as 40-50%. The results add to the growing evidence that progestogens may be mitogenic in breast tissue. Increased proliferation during hormonal contraception should be regarded as an unwanted and potentially hazardous side effect. Efforts should be made to define hormonal contraceptive regimens which minimize breast epithelial proliferation and to identify those women with the most pronounced proliferative response.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 35 条
[1]   ORAL-CONTRACEPTIVE USE INFLUENCES RESTING BREAST PROLIFERATION [J].
ANDERSON, TJ ;
BATTERSBY, S ;
KING, RJB ;
MCPHERSON, K ;
GOING, JJ .
HUMAN PATHOLOGY, 1989, 20 (12) :1139-1144
[2]   ANDROGENS INDUCE DIVERGENT PROLIFERATIVE RESPONSES IN HUMAN BREAST-CANCER CELL-LINES [J].
BIRRELL, SN ;
BENTEL, JM ;
HICKEY, TE ;
RICCIARDELLI, C ;
WEGER, MA ;
HORSFALL, DJ ;
TILLEY, WD .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 52 (05) :459-467
[3]   The role of progestins and antiprogestins in the treatment of breast cancer [J].
Bonney, RC .
ENDOCRINE-RELATED CANCER, 1996, 3 (02) :113-125
[4]   SERUM LEVELS OF 4-ANDROSTENE-3,17-DIONE IN MENSTRUATING AND POSTMENOPAUSAL WOMEN - EVALUATION OF A RADIOIMMUNOASSAY AND CORRELATION WITH BONE-MINERAL CONTENT AND ENDOMETRIAL PATHOLOGY [J].
BRODY, S ;
CARLSTROM, K ;
LAGRELIUS, A ;
LUNELL, NO ;
ROSENBORG, L .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1983, 62 (05) :531-534
[5]  
Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
[6]   Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques [J].
Cline, JM ;
Soderqvist, G ;
vonSchoultz, E ;
Skoog, L ;
vonSchoultz, B .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :93-100
[7]  
COSTA MJ, 1993, ACTA CYTOL, V37, P461
[8]  
FRANZEN S, 1968, ACTA RADIOL THER PHY, V7, P241
[9]  
GERDES J, 1991, AM J PATHOL, V138, P867
[10]   PROGESTIN EFFECT ON CELL-PROLIFERATION AND 17-BETA-HYDROXYSTEROID DEHYDROGENASE-ACTIVITY IN NORMAL HUMAN-BREAST CELLS IN CULTURE [J].
GOMPEL, A ;
MALET, C ;
SPRITZER, P ;
LALARDRIE, JP ;
KUTTENN, F ;
MAUVAISJARVIS, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) :1174-1180